Metabolic Effects of Clofibrate in Insulin-dependent Ketosis-prone Diabetic Man
Overview
Affiliations
This study examined the effects of clofibrate therapy on basal plasma substrate and hormone concentrations in ketosis-prone insulin-dependent diabetic man. A double-blind crossover design was utilized during a 3-mo period in which clofibrate treatment (1 g b.i.d.) was compared to that of a lactose placebo (1 g b.i.d.). Our results demonstrate that clofibrate treatment resulted in a significant reduction in the concentration of plasma glucose, ketone bodies, free fatty acids, triglyceride, and cholesterol in diabetic man. These beneficial effects were observed without demonstrable changes in circulating concentrations of insulin and glucagon. These observations suggest that in ketosis-prone diabetic man, clofibrate therapy may provide an adjunct to exogenous insulin administration.
Calvert G, Blight L, Franklin J, Oliver J, Wise P, Gallus A Eur J Clin Pharmacol. 1980; 17(5):355-62.
PMID: 6998709 DOI: 10.1007/BF00558448.
Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.
Murakami K, Nambu S, Koh H, Kobayashi M, Shigeta Y Br J Clin Pharmacol. 1984; 17(1):89-91.
PMID: 6362704 PMC: 1463305. DOI: 10.1111/j.1365-2125.1984.tb05005.x.
Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.
Daubresse J, DAIGNEUX D, Bruwier M, Luyckx A, Lefebvre P Br J Clin Pharmacol. 1979; 7(6):599-603.
PMID: 380614 PMC: 1429683. DOI: 10.1111/j.1365-2125.1979.tb04649.x.